On June 6, 2019, AHIP submitted comments to leaders of the House Ways and Means Committee and the House Energy and Commerce Committee on their discussion draft for bipartisan legislation addressing the Medicare Part D prescription drug program.
Our comments indicate our support for the implementation of a maximum out-of-pocket limit (MOOP) for Medicare Part D enrollees, but also emphasize that the draft legislation’s approach of pairing a MOOP with lower federal reinsurance subsidies would substantially increase government costs and the premiums that seniors pay. We also advocate for drug makers to finance part of the drug costs in the catastrophic phase of the Medicare Part D benefit.